Anavex Life Sciences Corp (AVXL)

[Steady_T]

I can only find one accepted surrogate endpoint for Alzheimer's, that is reduction in A beta plaque.

Anavex does have several biomarkers that it is tracking in the AD trial but so far those are not accepted surrogate biomarkers.
How the FDA will evaluate those biomarkers is an open question. For example, Anavex has data showing activation of genetic pathways as a result of taking 2-73.
What the FDA will make of that data is unknown. Likely they will look at that and say it is interesting, do you have any proof that it results in clinical improvement?

Anavex is on the bleeding edge of AD research and drug development.